Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Luis G. Paz-Ares, MD, Phd provides an overview of his presentation at ASCO 2019 entitled Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent...
Author: PharmaMar
Added: 06/01/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Small Cell Lung Cancer